Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) will host an investor webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET to announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program.
The live webcast will be available in the investor section of the company's website and will be archived for 60 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – BEAM
In the Feb 24 session, BEAM gained 13.98%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.3% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 29 | Earnings call scheduling | Neutral | -0.8% | Announced Q3 2024 earnings call and ASH abstracts webcast timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past earnings/conference scheduling produced a small negative move, indicating modest sensitivity to such announcements.
Recent history for BEAM around combined earnings and conference-call announcements shows limited price impact. On Nov 5, 2024, when the company scheduled a call for Q3 2024 results and ASH abstracts, the stock moved -0.81%. Today’s news again pre-announces timing for financial results and pipeline discussion, fitting a pattern where logistics-focused updates act mainly as informational events rather than major trading catalysts.
Key Terms
investor webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.
The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
